What Researchers Did
Researchers conducted a pilot study to assess platelet function in six patients receiving hyperbaric oxygen therapy for osteoradionecrosis prophylaxis.
What They Found
In this pilot study of 6 patients, blood samples were collected before and after the first, tenth, and twentieth hyperbaric oxygen treatments (2.0 ATA O2 for 2 hours, 6 days/week). Measurements of platelet aggregation, ATP release, and activated αIIbβ3 integrin expression showed no significant differences due to hyperbaric oxygen exposures.
What This Means for Canadian Patients
Canadian patients undergoing hyperbaric oxygen therapy may not experience changes in their platelet function, suggesting this treatment does not negatively impact blood clotting mechanisms. This finding could reassure patients and clinicians about the safety profile of hyperbaric oxygen therapy concerning platelet activity.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A significant limitation of this study is its small sample size of only six patients, which limits the generalizability of the findings.